Firefire
2021-07-02
Great!
J&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant<blockquote>强生Covid-19疫苗显示出预防德尔塔变异毒株病的初步迹象</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":156231716,"tweetId":"156231716","gmtCreate":1625223849435,"gmtModify":1631893945024,"author":{"id":4088082880945180,"idStr":"4088082880945180","authorId":4088082880945180,"authorIdStr":"4088082880945180","name":"Firefire","avatar":"https://static.tigerbbs.com/46b724bd4ce7cc56dea4804cfe75606b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Great!</p></body></html>","htmlText":"<html><head></head><body><p>Great!</p></body></html>","text":"Great!","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/156231716","repostId":1190296598,"repostType":4,"repost":{"id":"1190296598","kind":"news","pubTimestamp":1625213296,"share":"https://www.laohu8.com/m/news/1190296598?lang=zh_CN&edition=full","pubTime":"2021-07-02 16:08","market":"us","language":"en","title":"J&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant<blockquote>强生Covid-19疫苗显示出预防德尔塔变异毒株病的初步迹象</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1190296598","media":"The Wall Street Journal","summary":"Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n\nJohnson & J","content":"<p> Vaccine triggered strong immune response in blood samples from eight vaccinated people. Johnson & Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.</p><p><blockquote>疫苗在八名接种者的血液样本中引发了强烈的免疫反应。强生公司表示，在一项小型实验室研究中，强生公司的sJNJ0.74%Covid-19疫苗显示出有希望的迹象，可以预防在美国和其他国家传播的德尔塔变异毒株。</blockquote></p><p> In laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&J said Thursday.</p><p><blockquote>强生周四表示，在实验室测试中，该疫苗在八名接种者的血液样本中引发了强烈的免疫反应。</blockquote></p><p> The positive performance adds to a growing set of evidence indicating currently authorized Covid-19 vaccines can safeguard against the Delta variant, which appears to be more contagious than earlier strains.</p><p><blockquote>积极的表现增加了越来越多的证据，表明目前授权的新冠肺炎疫苗可以预防德尔塔变异毒株病毒，这种病毒似乎比早期的毒株更具传染性。</blockquote></p><p> How well the J&J shot fares against the Delta variant has been closely watched by health authorities around the world.</p><p><blockquote>世界各地卫生当局都在密切关注强生疫苗对德尔塔变异毒株的疗效。</blockquote></p><p> Many countries have been counting on supplies, especially because the vaccine is simpler to ship, handle and store than the shots fromPfizerInc.PFE1.02%and its partnerBioNTech SEBNTX0.05%and fromModernaInc.MRNA0.06%</p><p><blockquote>许多国家一直依赖供应，特别是因为该疫苗比辉瑞Inc.PFE 1.02%及其合作伙伴BioNTech SEBNTX0.05%和ModernaInc.MRNA 0.06%的疫苗更容易运输、处理和储存</blockquote></p><p> The new findings “reinforce the ability of the Johnson & Johnson Covid-19 vaccine to help protect the health of people globally,” said J&J Chief Scientific Officer Paul Stoffels.</p><p><blockquote>J&J首席科学官Paul Stoffels表示，新发现“增强了强生新冠肺炎疫苗帮助保护全球人民健康的能力”。</blockquote></p><p> J&J also said its vaccine, in a separate study, generated immune responses against Covid-19 lasting for at least eight months, the most time that researchers were able to study the shot’s durability.</p><p><blockquote>强生公司还表示，在另一项研究中，其疫苗产生了针对Covid-19的免疫反应，持续了至少八个月，这是研究人员能够研究疫苗持久性的最长时间。</blockquote></p><p> J&J, of New Brunswick, N.J., released the high-level findings in a news release, not a detailed and peer-reviewed study.</p><p><blockquote>新泽西州新不伦瑞克的J&J在一份新闻稿中发布了高水平的发现，而不是一项详细的同行评审研究。</blockquote></p><p> The Delta variant first emerged in India late last year. Since then, it has spread rapidly, becoming the most common strain of the Covid-19 virus in several countries,including the U.S.</p><p><blockquote>德尔塔变异毒株于去年年底首次在印度出现。从那时起，它迅速传播，成为包括美国在内的几个国家最常见的Covid-19病毒株。</blockquote></p><p> The variant made up about 40% of positive Covid-19 test samples as of June 27, according to population genomics company Helix OpCo LLC, which collects and analyzes test samples from several U.S. states.</p><p><blockquote>根据人口基因组学公司Helix OpCo LLC的数据，截至6月27日，该变种约占Covid-19阳性检测样本的40%，该公司收集和分析了来自美国几个州的检测样本。</blockquote></p><p> Vaccination is the best defense against the Delta variant, according to public-health authorities, who have cited the threat posed by the strain in urging people to get immunized.</p><p><blockquote>公共卫生当局表示，接种疫苗是对抗德尔塔变异毒株的最佳防御措施，他们在敦促人们接种疫苗时引用了该毒株构成的威胁。</blockquote></p><p> So far, studies have indicated various vaccines appear effective against the Delta strain, especially once individuals have been fully vaccinated, though the shots aren’t as protective as they are against the original virus.</p><p><blockquote>到目前为止，研究表明，各种疫苗似乎对Delta毒株有效，特别是一旦个人完全接种了疫苗，尽管疫苗的保护作用不如对原始病毒的保护作用。</blockquote></p><p> Separate studies in England and Scotland found that vaccines from Pfizer-BioNTech andAstraZenecaPLCoffered substantial protection from the Delta variantagainst severe cases of Covid-19 and hospitalization.</p><p><blockquote>英格兰和苏格兰的单独研究发现，辉瑞-BioNTech和阿斯利康的疫苗对严重的Covid-19病例和住院治疗提供了针对Delta变种的实质性保护。</blockquote></p><p> England’s public health agency said an analysis of 14,000 cases found the Pfizer-BioNTech shot reduced the risk of hospitalization after infection with Delta by 96%.</p><p><blockquote>英格兰公共卫生机构表示，对14,000例病例的分析发现，辉瑞-BioNTech疫苗将感染Delta后住院的风险降低了96%。</blockquote></p><p> J&J’s single-dose shot is based on a different technology than the Pfizer-BioNTech and Moderna vaccines, but operates similar to AstraZeneca’s.</p><p><blockquote>强生的单剂量注射基于与辉瑞-BioNTech和Moderna疫苗不同的技术，但操作与阿斯利康的类似。</blockquote></p><p> J&J’s shot uses a modified version of the virus responsible for the common cold, to carry genetic instructions teaching cells how to make the spike protein that juts from the surface of the coronavirus.</p><p><blockquote>强生的疫苗使用了导致普通感冒的病毒的改良版本，携带遗传指令，教导细胞如何制造从冠状病毒表面伸出的刺突蛋白。</blockquote></p><p> Production of the spike protein, in turn,prompts the immune system to develop molecular defensesagainst the coronavirus.</p><p><blockquote>反过来，刺突蛋白的产生促使免疫系统发展针对冠状病毒的分子防御。</blockquote></p><p> In its large, pivotal study, the J&J vaccine was 66% effective in protecting against Covid-19 and 85% effective against severe disease. The shot appeared to be less effective in South Africa, where the variant now called Beta was circulating.</p><p><blockquote>在其大型关键研究中，强生疫苗预防Covid-19的有效率为66%，预防严重疾病的有效率为85%。这种疫苗在南非似乎不太有效，现在被称为Beta的变种正在那里传播。</blockquote></p><p> Overall, however, it was highly effective in places where variants were spreading during the trial.</p><p><blockquote>然而，总体而言，它在试验期间变异传播的地方非常有效。</blockquote></p><p> J&J said the immune response found in its recent laboratory study was higher for the Delta variant than for Beta.</p><p><blockquote>强生表示，其最近的实验室研究发现，德尔塔变异毒株的免疫反应高于贝塔。</blockquote></p><p> The study looked at blood samples from eight people in the J&J vaccine’s Phase 3 trial. The study found the shot triggered strong levels of neutralizing antibodies, agents of the immune system thought to be most effective fighting viruses.</p><p><blockquote>该研究观察了强生疫苗三期试验中八人的血液样本。研究发现，注射会引发高水平的中和抗体，这是免疫系统中被认为是对抗病毒最有效的药物。</blockquote></p><p> Data on the durability of the vaccine’s protection came from a separate small study by Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop the J&J vaccine.</p><p><blockquote>有关疫苗保护持久性的数据来自波士顿贝斯以色列女执事医疗中心的免疫学家丹·巴鲁奇(Dan Barouch)的另一项小型研究，他帮助开发了强生疫苗。</blockquote></p><p> The study found that strong neutralizing-antibody and other immune responses to Covid-19, including to the Delta strain, persisted for the eight months examined, J&J said.</p><p><blockquote>J&J表示，该研究发现，对Covid-19（包括Delta毒株）的强烈中和抗体和其他免疫反应持续了八个月。</blockquote></p><p> The U.S. Food and Drug Administrationauthorized J&J’s shotin February.</p><p><blockquote>美国。美国食品和药物管理局二月份批准了强生的注射。</blockquote></p><p> In April, federal health authorities temporarily recommended pausing use of J&J’s vaccine while they investigated a blood-clotting condition among people who got the shot.</p><p><blockquote>今年4月，联邦卫生当局在调查接种疫苗者的凝血状况时，暂时建议暂停使用强生疫苗。</blockquote></p><p> Theauthorities lifted the pauseshortly after, however, saying the benefits of the vaccine outweighed the risk and issuing recommendations for treating the rare condition.</p><p><blockquote>然而，当局不久后解除了暂停，称疫苗的益处大于风险，并发布了治疗这种罕见疾病的建议。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant<blockquote>强生Covid-19疫苗显示出预防德尔塔变异毒株病的初步迹象</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Covid-19 Vaccine Shows Promising Preliminary Signs of Protecting Against Delta Variant<blockquote>强生Covid-19疫苗显示出预防德尔塔变异毒株病的初步迹象</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-07-02 16:08</span>\n</p>\n</h4>\n</header>\n<article>\n<p> Vaccine triggered strong immune response in blood samples from eight vaccinated people. Johnson & Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.</p><p><blockquote>疫苗在八名接种者的血液样本中引发了强烈的免疫反应。强生公司表示，在一项小型实验室研究中，强生公司的sJNJ0.74%Covid-19疫苗显示出有希望的迹象，可以预防在美国和其他国家传播的德尔塔变异毒株。</blockquote></p><p> In laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&J said Thursday.</p><p><blockquote>强生周四表示，在实验室测试中，该疫苗在八名接种者的血液样本中引发了强烈的免疫反应。</blockquote></p><p> The positive performance adds to a growing set of evidence indicating currently authorized Covid-19 vaccines can safeguard against the Delta variant, which appears to be more contagious than earlier strains.</p><p><blockquote>积极的表现增加了越来越多的证据，表明目前授权的新冠肺炎疫苗可以预防德尔塔变异毒株病毒，这种病毒似乎比早期的毒株更具传染性。</blockquote></p><p> How well the J&J shot fares against the Delta variant has been closely watched by health authorities around the world.</p><p><blockquote>世界各地卫生当局都在密切关注强生疫苗对德尔塔变异毒株的疗效。</blockquote></p><p> Many countries have been counting on supplies, especially because the vaccine is simpler to ship, handle and store than the shots fromPfizerInc.PFE1.02%and its partnerBioNTech SEBNTX0.05%and fromModernaInc.MRNA0.06%</p><p><blockquote>许多国家一直依赖供应，特别是因为该疫苗比辉瑞Inc.PFE 1.02%及其合作伙伴BioNTech SEBNTX0.05%和ModernaInc.MRNA 0.06%的疫苗更容易运输、处理和储存</blockquote></p><p> The new findings “reinforce the ability of the Johnson & Johnson Covid-19 vaccine to help protect the health of people globally,” said J&J Chief Scientific Officer Paul Stoffels.</p><p><blockquote>J&J首席科学官Paul Stoffels表示，新发现“增强了强生新冠肺炎疫苗帮助保护全球人民健康的能力”。</blockquote></p><p> J&J also said its vaccine, in a separate study, generated immune responses against Covid-19 lasting for at least eight months, the most time that researchers were able to study the shot’s durability.</p><p><blockquote>强生公司还表示，在另一项研究中，其疫苗产生了针对Covid-19的免疫反应，持续了至少八个月，这是研究人员能够研究疫苗持久性的最长时间。</blockquote></p><p> J&J, of New Brunswick, N.J., released the high-level findings in a news release, not a detailed and peer-reviewed study.</p><p><blockquote>新泽西州新不伦瑞克的J&J在一份新闻稿中发布了高水平的发现，而不是一项详细的同行评审研究。</blockquote></p><p> The Delta variant first emerged in India late last year. Since then, it has spread rapidly, becoming the most common strain of the Covid-19 virus in several countries,including the U.S.</p><p><blockquote>德尔塔变异毒株于去年年底首次在印度出现。从那时起，它迅速传播，成为包括美国在内的几个国家最常见的Covid-19病毒株。</blockquote></p><p> The variant made up about 40% of positive Covid-19 test samples as of June 27, according to population genomics company Helix OpCo LLC, which collects and analyzes test samples from several U.S. states.</p><p><blockquote>根据人口基因组学公司Helix OpCo LLC的数据，截至6月27日，该变种约占Covid-19阳性检测样本的40%，该公司收集和分析了来自美国几个州的检测样本。</blockquote></p><p> Vaccination is the best defense against the Delta variant, according to public-health authorities, who have cited the threat posed by the strain in urging people to get immunized.</p><p><blockquote>公共卫生当局表示，接种疫苗是对抗德尔塔变异毒株的最佳防御措施，他们在敦促人们接种疫苗时引用了该毒株构成的威胁。</blockquote></p><p> So far, studies have indicated various vaccines appear effective against the Delta strain, especially once individuals have been fully vaccinated, though the shots aren’t as protective as they are against the original virus.</p><p><blockquote>到目前为止，研究表明，各种疫苗似乎对Delta毒株有效，特别是一旦个人完全接种了疫苗，尽管疫苗的保护作用不如对原始病毒的保护作用。</blockquote></p><p> Separate studies in England and Scotland found that vaccines from Pfizer-BioNTech andAstraZenecaPLCoffered substantial protection from the Delta variantagainst severe cases of Covid-19 and hospitalization.</p><p><blockquote>英格兰和苏格兰的单独研究发现，辉瑞-BioNTech和阿斯利康的疫苗对严重的Covid-19病例和住院治疗提供了针对Delta变种的实质性保护。</blockquote></p><p> England’s public health agency said an analysis of 14,000 cases found the Pfizer-BioNTech shot reduced the risk of hospitalization after infection with Delta by 96%.</p><p><blockquote>英格兰公共卫生机构表示，对14,000例病例的分析发现，辉瑞-BioNTech疫苗将感染Delta后住院的风险降低了96%。</blockquote></p><p> J&J’s single-dose shot is based on a different technology than the Pfizer-BioNTech and Moderna vaccines, but operates similar to AstraZeneca’s.</p><p><blockquote>强生的单剂量注射基于与辉瑞-BioNTech和Moderna疫苗不同的技术，但操作与阿斯利康的类似。</blockquote></p><p> J&J’s shot uses a modified version of the virus responsible for the common cold, to carry genetic instructions teaching cells how to make the spike protein that juts from the surface of the coronavirus.</p><p><blockquote>强生的疫苗使用了导致普通感冒的病毒的改良版本，携带遗传指令，教导细胞如何制造从冠状病毒表面伸出的刺突蛋白。</blockquote></p><p> Production of the spike protein, in turn,prompts the immune system to develop molecular defensesagainst the coronavirus.</p><p><blockquote>反过来，刺突蛋白的产生促使免疫系统发展针对冠状病毒的分子防御。</blockquote></p><p> In its large, pivotal study, the J&J vaccine was 66% effective in protecting against Covid-19 and 85% effective against severe disease. The shot appeared to be less effective in South Africa, where the variant now called Beta was circulating.</p><p><blockquote>在其大型关键研究中，强生疫苗预防Covid-19的有效率为66%，预防严重疾病的有效率为85%。这种疫苗在南非似乎不太有效，现在被称为Beta的变种正在那里传播。</blockquote></p><p> Overall, however, it was highly effective in places where variants were spreading during the trial.</p><p><blockquote>然而，总体而言，它在试验期间变异传播的地方非常有效。</blockquote></p><p> J&J said the immune response found in its recent laboratory study was higher for the Delta variant than for Beta.</p><p><blockquote>强生表示，其最近的实验室研究发现，德尔塔变异毒株的免疫反应高于贝塔。</blockquote></p><p> The study looked at blood samples from eight people in the J&J vaccine’s Phase 3 trial. The study found the shot triggered strong levels of neutralizing antibodies, agents of the immune system thought to be most effective fighting viruses.</p><p><blockquote>该研究观察了强生疫苗三期试验中八人的血液样本。研究发现，注射会引发高水平的中和抗体，这是免疫系统中被认为是对抗病毒最有效的药物。</blockquote></p><p> Data on the durability of the vaccine’s protection came from a separate small study by Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop the J&J vaccine.</p><p><blockquote>有关疫苗保护持久性的数据来自波士顿贝斯以色列女执事医疗中心的免疫学家丹·巴鲁奇(Dan Barouch)的另一项小型研究，他帮助开发了强生疫苗。</blockquote></p><p> The study found that strong neutralizing-antibody and other immune responses to Covid-19, including to the Delta strain, persisted for the eight months examined, J&J said.</p><p><blockquote>J&J表示，该研究发现，对Covid-19（包括Delta毒株）的强烈中和抗体和其他免疫反应持续了八个月。</blockquote></p><p> The U.S. Food and Drug Administrationauthorized J&J’s shotin February.</p><p><blockquote>美国。美国食品和药物管理局二月份批准了强生的注射。</blockquote></p><p> In April, federal health authorities temporarily recommended pausing use of J&J’s vaccine while they investigated a blood-clotting condition among people who got the shot.</p><p><blockquote>今年4月，联邦卫生当局在调查接种疫苗者的凝血状况时，暂时建议暂停使用强生疫苗。</blockquote></p><p> Theauthorities lifted the pauseshortly after, however, saying the benefits of the vaccine outweighed the risk and issuing recommendations for treating the rare condition.</p><p><blockquote>然而，当局不久后解除了暂停，称疫苗的益处大于风险，并发布了治疗这种罕见疾病的建议。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/j-j-covid-19-vaccine-shows-promising-preliminary-signs-of-protecting-against-delta-variant-11625184011?mod=business_lead_pos2\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.wsj.com/articles/j-j-covid-19-vaccine-shows-promising-preliminary-signs-of-protecting-against-delta-variant-11625184011?mod=business_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190296598","content_text":"Vaccine triggered strong immune response in blood samples from eight vaccinated people.\n\nJohnson & Johnson’sJNJ0.74%Covid-19 vaccine showed promising signs in a small laboratory study of protecting against the Delta variant spreading across the U.S. and other countries, the company said.\nIn laboratory testing, the vaccine triggered a strong immune response in blood samples taken from eight vaccinated people, J&J said Thursday.\nThe positive performance adds to a growing set of evidence indicating currently authorized Covid-19 vaccines can safeguard against the Delta variant, which appears to be more contagious than earlier strains.\nHow well the J&J shot fares against the Delta variant has been closely watched by health authorities around the world.\nMany countries have been counting on supplies, especially because the vaccine is simpler to ship, handle and store than the shots fromPfizerInc.PFE1.02%and its partnerBioNTech SEBNTX0.05%and fromModernaInc.MRNA0.06%\nThe new findings “reinforce the ability of the Johnson & Johnson Covid-19 vaccine to help protect the health of people globally,” said J&J Chief Scientific Officer Paul Stoffels.\nJ&J also said its vaccine, in a separate study, generated immune responses against Covid-19 lasting for at least eight months, the most time that researchers were able to study the shot’s durability.\nJ&J, of New Brunswick, N.J., released the high-level findings in a news release, not a detailed and peer-reviewed study.\nThe Delta variant first emerged in India late last year. Since then, it has spread rapidly, becoming the most common strain of the Covid-19 virus in several countries,including the U.S.\nThe variant made up about 40% of positive Covid-19 test samples as of June 27, according to population genomics company Helix OpCo LLC, which collects and analyzes test samples from several U.S. states.\nVaccination is the best defense against the Delta variant, according to public-health authorities, who have cited the threat posed by the strain in urging people to get immunized.\nSo far, studies have indicated various vaccines appear effective against the Delta strain, especially once individuals have been fully vaccinated, though the shots aren’t as protective as they are against the original virus.\nSeparate studies in England and Scotland found that vaccines from Pfizer-BioNTech andAstraZenecaPLCoffered substantial protection from the Delta variantagainst severe cases of Covid-19 and hospitalization.\nEngland’s public health agency said an analysis of 14,000 cases found the Pfizer-BioNTech shot reduced the risk of hospitalization after infection with Delta by 96%.\nJ&J’s single-dose shot is based on a different technology than the Pfizer-BioNTech and Moderna vaccines, but operates similar to AstraZeneca’s.\nJ&J’s shot uses a modified version of the virus responsible for the common cold, to carry genetic instructions teaching cells how to make the spike protein that juts from the surface of the coronavirus.\nProduction of the spike protein, in turn,prompts the immune system to develop molecular defensesagainst the coronavirus.\nIn its large, pivotal study, the J&J vaccine was 66% effective in protecting against Covid-19 and 85% effective against severe disease. The shot appeared to be less effective in South Africa, where the variant now called Beta was circulating.\nOverall, however, it was highly effective in places where variants were spreading during the trial.\nJ&J said the immune response found in its recent laboratory study was higher for the Delta variant than for Beta.\nThe study looked at blood samples from eight people in the J&J vaccine’s Phase 3 trial. The study found the shot triggered strong levels of neutralizing antibodies, agents of the immune system thought to be most effective fighting viruses.\nData on the durability of the vaccine’s protection came from a separate small study by Dan Barouch, an immunologist at Beth Israel Deaconess Medical Center in Boston who helped develop the J&J vaccine.\nThe study found that strong neutralizing-antibody and other immune responses to Covid-19, including to the Delta strain, persisted for the eight months examined, J&J said.\nThe U.S. Food and Drug Administrationauthorized J&J’s shotin February.\nIn April, federal health authorities temporarily recommended pausing use of J&J’s vaccine while they investigated a blood-clotting condition among people who got the shot.\nTheauthorities lifted the pauseshortly after, however, saying the benefits of the vaccine outweighed the risk and issuing recommendations for treating the rare condition.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":232,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/156231716"}
精彩评论